| Since the application of the medicine for anti-tuberculosis, especially the clinical application of the INH,RFP and PIA of the short-term chemotherapy recommended by World Health Organization in recent years, anti-tuberculosis chemotherapy has been accepted as the most effective method to control tuberculosis.The recovery rate of these kinds of medicine for tuberculosis is very high, but there are side effects on liver poisoning from the use of them. The patients who receive the medicine treatment often experience drug-induced hepatotoxicity. The serious patients have to change the treatment plan and even to stop receiving the chemotherapy. So anti-tuberculosis drug-induced hepatotoxicity not only handicaps the treatment of anti-tuberculosis, but also aggravates patients' physical burden. The paper has the aim to study the raise of ALT or AST, namely the criterion for drug-induced hepatotocixity, and GSTM1 gene mutation, which are regarded as one of the source of anti-tuberculosis drug-induced hepatotoxicity. This research has the following purposes:To investigate the proportion of the only aminopherase which is caused by anti-tuberculosis drug-induced hepatotoxicity and the inclidence of anti-tuberculosis drug-induced hepatotoxicity;To explore the main organism of GSTM1 gene mutation in the process of anti-tuberculosis drug-induced hepatotoxicity. With the help of the research, we can early find out the virus of anti-tuberculosis drug-induced hepatotoxicity to make sure if the patient has mutation or not. And we can prevent serious drug-induced hepatitis and anti-tuberculosis drug-induced hepathotoxicity,. This investigation will also play an important role in preventing serious drug-induced hepatotoxicity, especially among those aged and weak people, the GSTM1 gene mutation individuals.The following findings have been made in the systemic research of relevant risk factors of anti-tuberculosis drug-induced hepatotoxicity and its organism:1. There will be a higher incidence of hepatotoxicity with the increases of ages. The incidence of those who are under 35 is 13.2%, those who are 35- 55 is 20.0%, and those who are under 55 is 31.0%. This conclusion is the same with the report from foreign countries. There is the possibility that the liver functions decrease with the increase of ages. The supersession of pharmaceuticals becomes slow and the density of pharmacecuticals in blood increases,. This is the reason of the increase of incidence of hepatotoxicity. 2. The incidences of hepatotoxicity of males and females are respectively 18.5% and 19.8%. This indicates anti-tuberculosis drug-induced hepatotoxicity has no relationship with gender. The conclusion in the paper is different form the report in other published document. So it needs further research on the conclusion that gender can be taken as the only risk factor of anti-tuberculosis drug-induced hepatotoxicity. From the diagram 3, we can see clearly that more than 50% of the patients have the symptom of anti-tuberculosis drug-induced hepatotoxicity after they receive the treatment within one month, 90% have the symtom within 3 months and only 5-6% after three month. This result is the same with the repot in published document.All the patients in this group receive muti-drug treatment. Most of the chemotherapy plan contains HR2 of HR, but Z uses the medicine only in the period of reinforcemnt. Therefore, it should be emphasized that patients are expected to receive at least one test of liver functions in the first two weeks of treatment. In the following period of reinforcement,the test should be carried out every two weeks. Since the incidence is low in the period of consolidation, so the test can be conducted once a month. 4. The relationship between anti-tuberculosis drug-induced hepatotoxicity and HBVM infection has been carefully studied. 39.5% of the patients with HBVM(+)have hepatotoxicity, which is higher than that of HBVM(-)group (15.9%). Among the hepatotoxicity patients, the HBVM(+)group,...
|
PDF Full Text Request